AURA (Aura Biosciences) EBITDA Margin %: 0.00% (As of Mar. 2026)


AURA Aura Biosciences Inc AURA
35 GF Score
Price $7.04
! 3 Warning Signs
View Full Analysis

What is Aura Biosciences EBITDA Margin %?

Aura Biosciences AURA +0.36% 35 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates AURA with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 945 Biotechnology companies, Aura Biosciences ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aura Biosciences's EBITDA for the three months ended in Mar. 2026 was $-34.59 Mil. Aura Biosciences's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Aura Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Aura Biosciences  (NAS:AURA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Aura Biosciences EBITDA Margin % Related Terms

Aura Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Aura Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aura Biosciences EBITDA Margin % Chart

Aura Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Aura Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AURA vs PHAT, SMNR, CTMX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Aura Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aura Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's EBITDA Margin % falls into.


AURA
35GF Score
Aura Biosciences Inc AURA
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aura Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Aura Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-111.662/0
= %

Aura Biosciences's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-34.592/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Aura Biosciences (AURA) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aura Biosciences and its competitors. According to the industry distribution chart, Aura Biosciences ranks #999999 out of 945 companies in the Biotechnology industry.
Is Aura Biosciences' EBITDA Margin % too high?
Aura Biosciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, Aura Biosciences ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aura Biosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Aura Biosciences' EBITDA Margin % compare to PHAT and SMNR?
According to the Biotechnology industry distribution chart, Aura Biosciences ranks #999999 out of 945 companies for EBITDA Margin %. This places Aura Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aura Biosciences and its competitors. Aura Biosciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aura Biosciences stock overvalued right now?
Aura Biosciences (AURA) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Aura Biosciences' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aura Biosciences (AURA), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aura Biosciences Business Description

Address 80 Guest Street, Boston, MA, USA, 02135
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
35GF Score

Get the complete analysis for AURA

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.04
Price